Eli Lilly and Company (LLY)
| Market Cap | 1.29T +37.6% |
| Revenue (ttm) | 86.46B +45.5% |
| Net Income | 27.58B +49.8% |
| EPS | 30.81 +50.7% |
| Shares Out | 890.75M |
| PE Ratio | 46.85 |
| Forward PE | 30.78 |
| Dividend | $6.92 (0.48%) |
| Ex-Dividend Date | Nov 13, 2026 |
| Volume | 2,084,332 |
| Open | 1,429.91 |
| Previous Close | 1,425.55 |
| Day's Range | 1,419.77 - 1,449.64 |
| 52-Week Range | 850.51 - 1,460.00 |
| Beta | 0.39 |
| Analysts | Buy |
| Price Target | 1,463.40 (+1.38%) |
| Earnings Date | Oct 29, 2026 |
About LLY
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial StatementsAnalyst Summary
According to 31 analysts, the average rating for LLY stock is "Buy." The 12-month stock price target is $1,463.4, which is an increase of 1.38% from the latest price.
News
Mapping the Market: Eli Lilly shares ready to rally again
Shares in Eli Lilly rose more than 70% from their 2026 low to the record high they hit on Thursday, and more gains could be in store, technical analysis indicates.
Lilly breaks ground in Pennsylvania's Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020
Facility will manufacture injectable medicines, including retatrutide Site will create 850 high-wage jobs and 2,000 construction jobs INDIANAPOLIS, Nov. 12, 2026 /PRNewswire/ -- Eli Lilly and Company ...
Nvidia CEO Out — 10 Stocks To Buy Before S&P 500 Hits 8,000
Nvidia (NVDA) is down over 30% from the highs with CEO Jensen Huang stepping down, yet Blanke Schein Wealth Management CIO Robert Schein says the stock is still a buy. He also names Broadcom (AVGO), A...
The Big 3: JNJ, LLY, AAPL
Amid the broader tech sell-off following Nvidia (NVDA) CEO Jensen Huang's resignation, Dan Deming looks to healthcare and “anti-AI” plays for stability. He says he's following the momentum in stocks i...
Eli Lilly Stock (LLY) Jumps as China Approves Its Weight-Loss Pill
China is a huge market with 1.4 billion people.
The world's most sophisticated drug companies are putting billions into vaccines — despite the political environment
Look at the promising data for Moderna and Merck's experimental cancer vaccine and the research suggesting the shingles vaccine can delay dementia.
Eli Lilly announces Orforglipron approved by China’s NMPA
Eli Lilly (LLY) China announced that its Orforglipron has been approved by China’s National Medical Products Administration, NMPA, for the launch of a Category 1 new drug, intended for adult…
China approves Eli Lilly's weight loss pill orforglipron
Eli Lilly on Thursday became the first drugmaker to have a GLP-1 weight-loss pill approved in China, giving it an edge over Danish rival Novo Nordisk (NOVOb.CO), opens new tab in the world's second-...
Eli Lilly announces 52-week results from TOGETHER-PsA Phase 3b open-label trial
Eli Lilly (LLY) announced detailed 52-week results showing improved and durable efficacy from the TOGETHER-PsA Phase 3b open-label clinical trial evaluating the concomitant use of Taltz and Zepbound c...
New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy, patient-reported and metabolic outcomes at one year in adults with psoriatic arthritis and obesity
Nearly three times as many patients taking Taltz and Zepbound achieved ≥ 50% reduction in psoriatic arthritis disease activity (ACR50) at one year compared to Taltz alone in first-of-its-kind TOGETHER...
3 Mega-Cap Stocks with a ‘Perfect 10’ Smart Score
Thermo Fisher ($TMO), Eli Lilly & Co ($LLY), and GE Aerospace ($GE) are three mega-cap stocks with a Perfect 10 Smart Score. The TipRanks Smart Score measures stocks on eight…
Life doesn't slow down, and Foundayo™ (orforglipron) patient Leanne Morgan is done waiting
After years of thinking she should be able to manage her weight on her own, Leanne shares how a conversation with her doctor led her to Foundayo, and why she encourages others to talk with their healt...
FDA warns of vision loss risk linked to popular GLP-1 drugs like Wegovy, Zepbound
The FDA is requiring the makers of all GLP-1 medications to add a warning about the potential increased risk of NAION. NAION is a rare condition caused by decreased blood flow to the front part of the...
FDA orders blindness risk warning on weight loss drugs
Companies making popular weight loss drugs, including Ozempic and Wegovy, will be required to add a warning label about a rare eye condition that can cause blindness, the US Food and Drug Administrati...
Monday's Final Takeaways: LLY Foundayo Update & Lame Duck Congress Session Starts
There were some quiet market movers even as a lot of the oxygen was taken by Nvidia (NVDA) and its investigation into CEO Jensen Huang. Marley Kayden and Sam Vadas turn to their top takeaways from Mon...
Eli Lilly's Weight-Loss Pill Shows Sleep Apnea Benefits. Can It Gain on Novo?
Lilly plans to seek FDA approval for Foundayo to treat sleep apnea, potentially giving its weight-loss pill an edge over Novo Nordisk's oral Wegovy.
Eli Lilly’s (LLY) Obesity Pill Found to Help with Sleep Apnea
Obesity medications have many health benefits.
Ozempic, Zepbound and other GLP-1 drugs have a possible risk of vision loss
Several medical studies have found that people taking GLP-1 medications have an elevated risk for nonarteritic anterior ischemic optic neuropathy, or NAION.
U.S. regulators are requiring the makers of blockbuster drugs like Ozempic and Zepbound to include warnings about a rare eye condition that can cause permanent vision loss
The FDA is requiring the makers of drugs like Ozempic and Zepbound to include warnings about a rare eye condition that can cause permanent vision loss.
Lilly's Foundayo pill cuts sleep apnea severity by up to 44% in late-stage trial, with an FDA filing planned by year-end
Eli Lilly's daily obesity pill Foundayo cut breathing interruptions during sleep by up to 44% in a year-long Phase 3 program. Lilly plans to seek U.S. approval for obstructive sleep apnea by the end o...
Eli Lilly Stock (LLY) Gains After Canada Recommends Public Reimbursement of Its Alzheimer’s Drug
The breakthrough medication is not cheap.
US FDA orders new eye risk warnings for Ozempic, Zepbound
The US FDA on Monday informed patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs used for weight loss and diabetes...
Lilly's weight-loss pill meets main goal in late-stage sleep apnea study
Eli Lilly said on Monday its oral weight-loss drug Foundayo significantly reduced breathing interruptions during sleep in obese adults with moderate-to-severe obstructive sleep apnea, meeting the...
Eli Lilly announces ‘positive’ results from Phase 3 study of Foundayo
Eli Lilly (LLY) and Company announced positive results from ATTAIN-OSA, a Phase 3 clinical program evaluating the efficacy and safety of Foundayo in adults with moderate-to-severe obstructive sleep ap...
Eli Lilly's Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
Eli Lilly said its new obesity pill, Foundayo, significantly reduced the severity of the most common sleep-related breathing disorder in a late-stage trial. The drugmaker plans to file by the end of ...